CAR Based Immunotherapy of Solid Tumours—A Clinically Based Review of Target Antigens

TY - JOUR

T1 - CAR Based Immunotherapy of Solid Tumours—A Clinically Based Review of Target Antigens

AU - Maher, John

AU - Davies, David

N1 - Publisher Copyright: © 2023 by the authors.

PY - 2023/2/10

Y1 - 2023/2/10

N2 - Immunotherapy with CAR-engineered immune cells has transformed the management of selected haematological cancers. However, solid tumours have proven much more difficult to control using this emerging therapeutic modality. In this review, we survey the clinical impact of solid tumour CAR-based immunotherapy, focusing on specific targets across a range of disease indications Among the many candidates which have been the subject of non-clinical CAR T-cell research, clinical data are available for studies involving 30 of these targets. Here, we map out this clinical experience, highlighting challenges such as immunogenicity and on-target off-tumour toxicity, an issue that has been both unexpected and devastating in some cases. We also summarise how regional delivery and repeated dosing have been used in an effort to enhance impact and safety. Finally, we consider how emerging armouring systems and multi-targeted CAR approaches might be used to enhance tumour access and better enable discrimination between healthy and transformed cell types.

AB - Immunotherapy with CAR-engineered immune cells has transformed the management of selected haematological cancers. However, solid tumours have proven much more difficult to control using this emerging therapeutic modality. In this review, we survey the clinical impact of solid tumour CAR-based immunotherapy, focusing on specific targets across a range of disease indications Among the many candidates which have been the subject of non-clinical CAR T-cell research, clinical data are available for studies involving 30 of these targets. Here, we map out this clinical experience, highlighting challenges such as immunogenicity and on-target off-tumour toxicity, an issue that has been both unexpected and devastating in some cases. We also summarise how regional delivery and repeated dosing have been used in an effort to enhance impact and safety. Finally, we consider how emerging armouring systems and multi-targeted CAR approaches might be used to enhance tumour access and better enable discrimination between healthy and transformed cell types.

KW - solid tumour

KW - chimeric antigen receptor

KW - T-cell

KW - NK cell

KW - target

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=85148959933&partnerID=8YFLogxK

U2 - 10.3390/biology12020287

DO - 10.3390/biology12020287

M3 - Review article

SN - 2079-7737

VL - 12

SP - 287

JO - Biology

JF - Biology

IS - 2

M1 - 287

ER -